Advertisement


Dawn Hershman, MD, on Breast Cancer Survivorship: Poster Discussion

2016 San Antonio Breast Cancer Symposium

Advertisement

Dawn Hershman, MD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, reviews findings on survivorship care plans, interventions to reduce chemotherapy-induced peripheral neuropathy, and the cardiac effects of aromatase inhibitors (Poster Discussion 4).



Related Videos

Breast Cancer

Lisa A. Carey, MD, on SABCS Meeting Highlights: Expert Perspective

Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into clinical practice.

Breast Cancer

Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results

Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).

Breast Cancer

Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).

Breast Cancer

Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective

Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)

Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).

Advertisement

Advertisement




Advertisement